Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-TAB1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human TAB1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-TAB1 antibody linked to 4-1BB (CD137) and CD3ζ signaling domains. And the vector product was designed for the treatment of Ovarian cancer.
Specific Inquiry
Add to Cart
Details
Target
TAB1
Targeting Cell Type
T cell
Targeting Diseases
Ovarian cancer
Generation
Second
Vector Name
pCDCAR1
Vector Length
~8kb
Vector Type
Lentiviral vector
Receptor Construction
scFv-41BB-CD3ζ
Discription of Signaling Cassetes
41BB CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity. CD3ζ CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Target
Clone
2D3
Host
Mouse
Target Species
Human, Mouse, Rat
Gene Name
TGF-Beta Activated Kinase 1 (MAP3K7) Binding Protein 1
TAB1; TGF-Beta Activated Kinase 1 (MAP3K7) Binding Protein 1; TAK1-Binding Protein 1; Mitogen-Activated Protein Kinase Kinase Kinase 7 Interacting Protein 1; Mitogen-Activated Protein Kinase Kinase Kinase 7-Interacting Protein 1; MAP3K7IP1; Transforming Growth Factor Beta-Activated Kinase-Binding Protein 1
Introduction
TAB1 was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. TAB1 interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of it is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may play a role as a mediator between TGF beta receptors and TAK1. TAB1 can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli.
Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
Customer Reviews and Q&As
There are currently no customer reviews or questions for Anti-TAB1 (2D3) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-YJ189). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.